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Background and Objectives
Intermittent pneumatic compression (IPC) is an effective form of deep vein thrombosis
prophylaxis for general surgery patients. The antithrombotic effect of IPC is thought to be
the result of increased venous velocity and stimulation of endogenous fibrinolysis. However,
the mechanism of enhanced fibrinolytic activity and the relative effects on normal and
postthrombotic veins have not been defined. The purposes of this study are 1) to quantity
changes in fibrinolytic activity with IPC; 2) to study the mechanism of fibrinolytic
enhancement with IPC; and 3) to evaluate whether postthrombotic patients have the same
capacity for fibrinolytic enhancement with IPC as do normal subjects.
Methods
Twelve volunteers (6 normal and 6 postthrombotic) had 5 IPC devices applied for 120
minutes in random fashion, 1 per week x 5 weeks. The devices included single-chamber,
sequential, foot, calf, and long-leg compression. Subjects had an indwelling antecubital
venous cannula placed for blood drawn at baseline, 60, 120, and 180 minutes after IPC
devices were applied. Global fibrinolytic activity (euglobulin fraction, fibrin plate assay),
tissue plasminogen activator (tPA) antigen (Ag) and activity (Act), plasminogen activator
inhibitor-1 (PAI-1) Ag and Act, alpha-2-antiplasmin-plasmin complexes, and von Willebrand
factor (vWF) antigen were assayed.
Results
A striking elevation in fibrinolytic activity was noted at 180 minutes with all devices in
normal subjects and postthrombotic patients (p = 0.01-0.0001); however, baseline and
stimulated fibrinolytic activity was attenuated in postthrombotic patients (<0.03). The tPA-
Act increased only in normal subjects (3.8 + 1.9%) (p = 0.057), despite a decrease in
plasma tPA-Ag, which was observed in both normal subjects (-12.4 + 3.8%) (p = 0.009)
and patients (-17.2 + 3.1%) (p = 0.001). PAI-1 -Ag decreased in both normal subjects
(-13.4 ± 3.8%) (p = 0.007) and patients (-12.0 + 3.1%) (p = 0.013) with a marked
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reduction in PAI-1 -Act in both normal subjects (p = 0.003) and patients (p = 0.004). There
were no changes in vWF, and alpha-2-antiplasmin-plasmin complexes increased only in
postthrombotic patients (p = 0.021).
Conclusions
Stimulation of endogenous fibrinolytic activity occurs after IPC, both in normal subjects and
postthrombotic patients; however, baseline and overall fibrinolytic response in
postthrombotic patients is reduced. The mechanism of increased fibrinolytic activity is likely
because of a reduction in PAI-1, with a resulting increase of tPA activity.
Prophylaxis for deep venous thrombosis (DVT) is man-
datory for patients at moderate and high risk for venous
thromboembolic complications. '-3 Intermittent pneumatic
compression (IPC) is an effective mechanical method of
DVT prophylaxis.' -3 Because IPC stimulates fibrinolytic
activity, its antithrombotic action appears to be due to
more than just a mechanical effect on blood flow.46 Inter-
mittent pneumatic compression potentially affects two of
the three limbs of Virchow's triad by increasing venous
blood flow velocity, thereby reducing stasis, and stimulat-
ing fibrinolytic activity, thereby altering hypercoagulabil-
ity.
Endogenous or stimulated fibrinolysis is the result of
activation of plasminogen to plasmin by one of two en-
dogenous plasminogen activators, tissue plasminogen ac-
tivator (tPA) and urokinase type plasminogen activator
(uPA). This activation sequence is balanced by inactiva-
tion (binding with inhibitors), especially of tPA by the
rapid acting inhibitor, plasminogen activator inhibitor-i
(PAI-1).7 The degree of endogenous fibrinolysis can be
measured and the components of the fibrinolytic system
can be quantified, thereby allowing one to study the mech-
anism of fibrinolytic response to a given stimulus.
Surgical patients at risk of having postoperative DVT
develop and those who have suffered venous thrombotic
complications have measurably reduced fibrinolytic activ-
ity.89 In addition, patients with an inadequate augmen-
tation of fibrinolytic activity with IPC are most likely to
have postoperative DVT develop.5
It appears that there is a link between development of
DVT and endogenous fibrinolytic activity, and under-
standing this aspect of the patients' endogenous regula-
tory systems is increasingly important, especially in light
of the multiple options for DVT prophylaxis. Because
patients with postoperative DVT have depressed endoge-
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nous fibrinolytic activity89 and patients with postthrom-
botic venous disease are at high risk ofDVT after surgical
procedures,2 it would be of value to know if the mecha-
nisms of enhanced fibrinolysis with IPC are operative in
these patients and whether it is quantifiably different from
that in normal subjects.
The purposes of this study are to quantify the enhanced
fibrinolytic activity with IPC, to clarify the mechanisms
of fibrinolytic enhancement with IPC; and to evaluate
whether postthrombotic patients have the same capacity




Twelve volunteers of 2 distinct groups were studied.
The first consisted of six healthy subjects (4 men, 2
women; mean age, 46 years; range, 25-68 years) with no
history or physical findings of venous or arterial disease
(normal subjects). Routine venous duplex examinations
were performed to exclude the presence of asymptomatic
DVT or evidence of previously undetected chronic venous
disease.
The second group consisted of six subjects (4 men, 2
women; mean age, 48 years; range, 31-66 years) with a
history of proximal DVT treated with long-term anticoag-
ulation and venous duplex evidence of recanalization and
thickened walls of their veins (postthrombotic patients).
Devices
Five IPC devices were studied in random sequence;
these included thigh length sequential compression (SCD;
Kendal Health Care Products Company, Mansfield, MA),
TSQ; calf-length sequential compression (SCD Kendal
Health Care Products Company, Mansfield, MA ), CSQ;
thigh-length single-chamber compression (DVT, 30
Flowtron; Huntleigh Health Care, Malapan, NJ), TSC;
calf-length single-chamber compression (Huntleigh
Health Care, Malapan, NJ), CSC; and the foot pump
(Plexipulse; NuTech, San Antonio, TX), FP.
Subjects were studied in the Clinical Research Center
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of Temple University Hospital, and each had five IPC
devices applied in random fashion, one per week x five
weeks. Each subject was studied at the same time of
day to avoid confounding results by the known diurnal
variations in fibrinolytic activity.'0 After resting in the
supine position with the head of the bed elevated for a
minimum of 15 minutes, each compression device was
applied for a period of 120 minutes, as per manufacturer's
instructions. An indwelling catheter was placed in an
antecubital vein, and blood samples were drawn without
application of a tourniquet. Blood samples were collected
into one-tenth volume of 3.8% sodium citrate at the fol-
lowing intervals: baseline (after rest period but before
compression), 60 minutes, 120 minutes, and 180 minutes
after the start of IPC. For measurement of tPA activity,
blood samples were collected into one-tenth volume of
acidified buffered citrate (0.45 M trisodium citrate to
which citric acid was added to pH 4.3). The acid pH
prevents the ongoing in vitro inactivation of tPA by com-
plex formation with PAI- 1. Plasma was harvested by cen-
trifugation at 2500g for 20 minutes within 30 minutes of
collection and stored in aliquots at -80 C.
Assays
Fibrin-Plate Assay
The overall fibrinolytic activity was assessed by mea-
suring the fibrinolytic activity of the euglobulin fraction
of plasma on a fibrin plate.""2 These were performed on
blood samples drawn at baseline and at 180 minutes. The
zone of fibrinolysis was quantified by comparison to a
known standard using streptokinase.
Tissue Plasminogen Activator and Plasminogen
Activator Inhibitor- 1
The plasma samples were assessed for tPA and PAI-I
antigens using enzyme-linked immunosorbent assays
from American Diagnostica, Inc (Greenwich, CT). The
tPA activity and PAI-I activity were measured using a
commercially available kit from American Diagnostica
(Greenwich, CT).
Plasmin Alpha-2-Antiplasmin Complex
Circulating plasmin is rapidly bound by its inhibitor
alpha-2-antiplasmin. To assess whether IPC results in
plasmin generation, plasma levels of plasmin alpha-2-
antiplasmin complexes were measured using an enzyme
immunoassay from Behringwerke AG, Germany.
von Willebrand Factor
von Willebrand factor (vWF-Ag) was measured as a
marker of endothelial stimulation. It was measured using
a sandwich enzyme-linked immunosorbent assay from
Diagnostica Stago (Seine, France). The protocol was ap-
proved by the Institutional Review Board of Temple Uni-
versity Health Sciences Center, and each subject signed
an informed consent.
Statistical Analysis
Analyses of mean differences in the various protein
measurements among devices, time points, and samples
were performed using general linear models. Devices and
time points were treated as with-person (repeated mea-
sures) factors. Probability values reported for those fac-
tors are based on the Huynh-Feldt adjustment.'3 Differ-
ences from baseline over time and percent change from
baseline were analyzed for each device and each group.
Changes in the measured parameters were quantitated and
reported for each group and each compression device.
To detect changes in tPA, PAI-1, alpha-2-antiplasmin-
plasmin complexes, and vWF, the endpoint was defined
as the mean levels observed at 120 and 180 minutes and
reported as percent change from baseline (mean ± stan-
dard error of the mean).
RESULTS
Fibrinolytic activity, measured by fibrin-plate assay,
was reduced significantly at baseline in postthrombotic
subjects compared with that of normal subjects (p <
0.01). Intermittent pneumatic compression increased fi-
brinolytic activity, both in normal subjects and postthrom-
botics (p = 0.01-0.001) (Table 1). The IPC-stimulated
fibrinolytic activity in postthrombotics was equivalent to
the baseline fibrinolytic activity of normal subjects.
Plasma levels of the measured proteins of the fibrino-
lytic system during IPC with each device are shown in
Figures 1 through 6. Analyses of the data using linear
models indicated that there were significant changes over
time in plasma levels of tPA antigen (p = 0.001), tPA
activity (p = 0.005), PAI-i antigen (p = 0.0001), and
PAI-I activity (p = 0.0007) but not vWF or alpha-2-
antiplasmin complexes. Changes in plasma fibrinolytic
activity and vWF during IPC are reported as percent
change from baseline in Table 2.
There were no differences observed between compres-
sion devices either for the fibrin-plate assay or any of the
other measurements. Although patients with postthrom-
botic venous disease had higher levels of vWF at baseline
(p = 0.07), vWF factor showed no change during IPC in
either group (Fig. 2, Table 2).
The tPA antigen decreased over time with IPC in both
normal subjects (p < 0.009) and postthrombotics (p <
0.001). Despite the drop in tPA-Ag, tPA activity increased
in both normal subjects and postthrombotics, achieving
significance only in normal subjects (p < 0.038).
Plasminogen activator inhibitor antigen decreased with
IPC in normal subjects (p < 0.001) and postthrombotics
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Table 1. FIBRIN-PLATE ASSAY AT BASELINE AND 180 MINUTES FOR EACH OF FIVE
COMPRESSION DEVICES*







































FP = foot pump; CSQ = calf sequential; CSC = calf single chamber; TSQ = thigh sequential; TSC = thigh single chamber.
* Values are given as SU/mL (streptokinase units per milliliter; mean ± SEM). Comparison of patients vs. normals for each device at baseline and 180 min: p < 0.01
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Figure 1. Plasma levels of von Willebrand factor dunng intermittent
pneumatic compression with each of five compression devices in nor-
mal subjects (top) and postthrombotic patients (bottom). Shown are
mean + standard error of the mean (n = 6). FP = foot pump, CSQ
= calf sequential, CSC = calf single chamber, TSQ = thigh sequential,
TSC = thigh single chamber.
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Figure 2. Plasma levels of tissue plasminogen activator antigen during
intermittent pneumatic compression with each of five compression
devices in normal subjects (top) and postthrombotic patients (bottom).
Shown are mean + standard error of the mean (n = 6). FP = foot
pump, CSQ = calf sequential, CSC = calf single chamber, TSQ =
thigh sequential, TSC = thigh single chamber.
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procoagulant proteins, and production of thromboregula-
Normals tory compounds.'4 Stimulation of the vascular endothe-
_0.11- lium by IPC of the extremities may alter the homeostatic
interactions of a number of these pathways,'4-16 although
e I T the focus of this report is the alteration of fibrinolytic
E . a 0activity.
,, 0.09; ; = 3 --iThe relation of endogenous fibrinolytic activity to post-
. F_; | operative DVT has been studied. Before specific measures
of the components of the fibrinolytic system, the preoper-
<0.07- ative euglobulin lysis time was shown to be a predictor
of postoperative DVT.9 During the postoperative period,
a transient fall in fibrinolytic activity commonly is ob-
served.8" 7"18
0ost 60 120 180 240 Intermittent pneumatic compression has been shown to
stimulate endogenous fibrinolytic activity in a number of
Post-Thrombotic Patients previous studies and can reduce or eliminate the postoper-
ative depression in fibrinolytic activity.4-6 19 Although the
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lo10Figure 3. Plasma levels of tissue plasminogen activator activity during OM
intermittent pneumatic compression with each of five compression
devices in normal subjects (top) and postthrombotic patients (bottom). _ ____________l
Shown are mean + standard error of the mean (n = 6). FP = foot 0°
pump, CSQ = calf sequential, CSC = calf single chamber, TSQ = 0 60 120 180 240
thigh sequential, TSC = thigh single chamber.
:Post-Thrombotic Patients
40< T
(p < 0.013) and was accompanied by a reduction in PAI-E
1 activity in normal subjects (p < 0.003) and postthrom- " 30
botic patients (p < 0.004).
Changes in alpha 2-antiplasmin-plasmin complexes di- -
verged between the two subject groups. An increase was * 20
observed in postthrombotic patients (p = 0.021), whereas . | TSQ
in normal subjects, there was no significant change, al- - -o- csc
though the mean levels at endpoint were lower than at 010- CSQ
baseline (Table 2). The difference between normal sub- ; ^ TSC
jects and postthrombotic patients was significant (p = | FP
0.014). 0 60 120 180 240
Time (min)
DISCUSSION Figure 4. Plasma levels of plasminogen activator inhibitor-i-antigenduring intermittent pneumatic compression with each of five compres-
sion devices in normal subjects (top) and postthrombotic patients (bot-Vascular endothelium plays an important antithrom- tom). Shown are mean + standard error of the mean (n = 6). FP =
botic role by a number of separate but interrelated mecha- foot pump, CSQ = calf sequential, CSC = calf single chamber, TSQ
nisms, including regulation of fibrinolysis, inhibition of = thigh sequential, TSC = thigh single chamber.
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Figure 5. Plasma levels of plasminogen activator inhibitor-1 during
intermittent pneumatic compression with each of five compression
devices in normal subjects (top) and postthrombotic patients (bottom).
Shown are mean + standard error of the mean (n = 6). FP = foot
pump, CSQ = calf sequential, CSC = calf single chamber, TSQ =
thigh sequential, TSC = thigh single chamber.
mechanism of enhanced fibrinolytic activity with IPC has
not been clarified previously, it generally has been consid-
ered that tPA release from endothelial cells was stimu-
lated by IPC.45 This presumed mechanism of action has
led to expressions of concern that IPC may be thrombo-
genic due to depletion of intravascular plasminogen acti-
vator.20
Our data show that IPC stimulates endogenous fibrino-
lytic activity in both normal subjects and postthrombotic
patients. Not surprisingly, postthrombotic patients have
significantly reduced baseline fibrinolytic activity, and
when stimulated by IPC, increased their fibrinolytic activ-
ity to levels observed in normal subjects at baseline. This
may be related to chronic endothelial dysfunction.
The increase in fibrinolytic activity is not because of
an increase of tPA being released from endothelial cells
into the circulation. There was no increase in tPA antigen
with compression, nor was there any change in vWF,
another marker for endothelial secretion.
The main finding in this study is that IPC enhanced
plasma fibrinolytic activity associated with a decrease in
plasma tPA antigen, PAI-I antigen, and PAI-I activity,
but with an increase in tPA activity. The tPA activity in
blood is regulated by the specific fast-acting inhibitor,
PAI-1. The tPA antigen levels reflect both free tPA plus
tPA bound to PAI-I and thus do not represent only active
tPA. Therefore, tPA activity was measured directly in
this study. Intermittent pneumatic compression caused a
decrease in PAI-i antigen with a corresponding decline
in PAI-I activity (Table 2). The observed reduction in
PAI-I and the drop in tPA-Ag may be related to an in-
creased clearance of PAI-I and PAI-i -tPA complexes.
Because most of the circulating tPA is bound to PAI-1,
clearance of these complexes would result in a reduction













Figure 6. Plasma levels of alpha-2-antiplasmin-plasmin complexes
during intermittent pneumatic compression with each of five compres-
sion devices in normal subjects (top) and postthrombotic patients (bot-
tom). Shown are mean + standard error of the mean (n = 6). FP =
foot pump, CSQ = calf sequential, CSC = calf single chamber, TSQ
= thigh sequential, TSC = thigh single chamber.
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Table 2. CHANGES IN PLASMA FIBRINOLYTIC SYSTEM AND vWF DURING
INTERMITTENT PNEUMATIC COMPRESSION: BASELINE, ENDPOINT AND PERCENT
CHANGE TO ENDPOINT BY GROUP*
Group Baseline Endpoint % Change p



















NS = not significant.
* Shown are the changes (mean ± SEM for five devices) from baseline to the endpoint. The endpoint was defined as the mean of the levels observed at 120 and
180 min in each study.
Given the relative excess of PAI-I over tPA in the
circulation, enhanced clearance of PAI-1 and tPA-PAI-
complexes may by itself not be an adequate explanation
for the net increase in tPA activity. We postulate that,
overall, there may be an alteration in the balance between
plasma tPA and PAI- 1 activities induced by IPC, and this
may be related to a differential secretion of tPA and PAI-
1 from endothelial cells, with the net effect favoring ex-
pression of tPA activity. The effects induced by IPC may
be analogous to the diurnal changes observed in the activi-
ties of these plasma proteins.2' In normal subjects, there is
an increase in tPA activity in the evening with substantial
decreases in the plasma levels of PAI-I activity, tPA-
PAI-I complex, and total tPA.2' It has been suggested
that both PAI-I secretion and tPA secretion are increased
in the morning, but PAI-I secretion decreases more dur-
ing the day, resulting in higher levels of active tPA in
the evening.2' Thus, it is conceivable that a similar differ-
ential effect on the endothelial secretion of tPA and PAI-
1 may be induced by IPC with a relative increase in
tPA secretion leading to enhanced fibrinolytic activity.
Interestingly, we found no significant change in plasma
vWF, a protein also secreted from endothelial cells, sug-
gesting that the effect of IPC on endothelial tPA secretion
is relatively subtle and that IPC does induce a nonspecific
perturbation of the endothelium. Relatively small in-
creases in tPA secretion may be responsible for enhanced
fibrinolytic activity in the face of altered regulation by
PAI-1. If this were indeed the case, tPA activity is more
a function of the PAI-I activity than the total tPA in
circulation.2' This also explains the observed increased
fibrinolytic activity and increased tPA activity despite a
modest fall in tPA-Ag.
Although many factors are know to stimulate release
of PAI-1, conditions associated with its clearance from
the circulation are not well defined. The observations of
this study are supported by the findings of Jacobs et al.,6
who reported that sequential gradient IPC produced short-
ened euglobulin lysis times associated with a reduction
of PAI-1. Additional indirect evidence supporting these
data is that increased PAI-I is responsible for the associa-
tion between reduced endogenous fibrinolysis and DVT.22
The variation in PAI-i levels rather than tPA is thought
to be responsible for the diurnal variation of fibrinolytic
activity and correlate with myocardial infarction.'0
Although we believe that the predominant mechanism
of fibrinolytic enhancement by IPC is reduction of PAI-
1, the increased fibrinolytic activity may not be solely
due to changes in tPA. After a variety of stimuli, endothe-
lial cells preferentially synthesize and release another
plasminogen activator, uPA, which typically activates
plasminogen in the fluid phase and down regulates tPA.'4
The PAI-I binds to uPA as well, and a reduction in PAI-
1 may result in increased uPA activity. Although we did
not measure uPA, it is possible that it contributed to over-
all fibrinolytic activity after IPC, and this might explain
the marked increase in overall fibrinolytic activity com-
pared to the modest elevation of tPA-Act. Moreover, it
is conceivable that IPC induces changes in other plasma
and endothelial mechanisms that contribute to its anti-
thrombotic effect. Recent studies from our laboratory in-
dicate that IPC induces an increase in plasma levels of
tissue factor pathway inhibitor, the major physiologic in-
hibitor of the tissue factor-dependent pathway of blood
coagulation.23
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tients; however, it too may play a direct role in fibrinolysis
by stimulating the production of tPA,4 and IPC has been
shown to increase the production of prostacycline.25
We did not find any differences between the various
compression devices with respect to measured changes
in plasma. The limited number of subjects in this study
probably was insufficient to show the differences between
the devices.26
In summary, IPC stimulates fibrinolytic activity in nor-
mal subjects and postthrombotic patients; however, the
overall fibrinolytic activity is attenuated in postthrombotic
patients. We propose that the increase in fibrinolytic activ-
ity is related to a reduction in PAI-1 levels associated
with a resulting increase in tPA activity. These findings
underscore the important role of PAI-I in regulating the
endogenous fibrinolytic system.
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Discussion
DR. JAMES 0. MENZOIAN (Boston, Massachusetts): This rep-
resents another fine piece of work by Dr. Comerota and his
associates.
Over the years, he has been trying to educate us especially
in the area of deep venous thrombosis and prophylaxis against
deep venous thrombosis.
It is well established that intermittent pneumatic compression
is efficacious in decreasing the incidence of deep venous throm-
bosis, and presumably by two mechanisms. One is increasing
venous flow as measured by Duplex scans of the popliteal vein
and femoral vein, and also by enhancing fibrinolysis. Today's
study by Dr. Comerota shows us that the mechanism by which
it enhances fibrinolysis is by a reduction in the amount of plas-
minogen activator inhibitor. I have a few questions, if I may,
Dr. Comerota.
First, you showed in your subjects that the lytic activity was
enhanced both in the healthy subjects and in those subjects with
post-thrombotic syndrome, yet quantitatively there was less of
a response in those subjects with post-thrombotic syndrome.
Could you comment on the mechanism by which that could be,
and does that have any clinical significance?
Second, the effect of intermittent pneumatic compression
seemed to be fairly selective because it inhibited the plasmino-
gen activator inhibitor, but it did not have any effect on the
release of von Willebrand factor. Could you comment on that
specificity of intermittent pneumatic compression?
Third, after initiation of intermittent pneumatic compression,
when did this onset of fibrinolysis manifest itself and how long
